[go: up one dir, main page]

PL1753723T3 - Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych - Google Patents

Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych

Info

Publication number
PL1753723T3
PL1753723T3 PL05752901T PL05752901T PL1753723T3 PL 1753723 T3 PL1753723 T3 PL 1753723T3 PL 05752901 T PL05752901 T PL 05752901T PL 05752901 T PL05752901 T PL 05752901T PL 1753723 T3 PL1753723 T3 PL 1753723T3
Authority
PL
Poland
Prior art keywords
substituted quinoline
quinoline derivatives
mitotic kinesin
kinesin inhibitors
compounds
Prior art date
Application number
PL05752901T
Other languages
English (en)
Inventor
W ; Wang
R ; Constantine
L ; Lagniton
K ; Bair
Original Assignee
Novartis Vaccines & Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostics Inc filed Critical Novartis Vaccines & Diagnostics Inc
Publication of PL1753723T3 publication Critical patent/PL1753723T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL05752901T 2004-05-21 2005-05-19 Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych PL1753723T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57312004P 2004-05-21 2004-05-21
EP05752901A EP1753723B1 (en) 2004-05-21 2005-05-19 Substituted quinoline derivatives as mitotic kinesin inhibitors
PCT/US2005/017961 WO2005113507A1 (en) 2004-05-21 2005-05-19 Substituted quinoline derivatives as mitotic kinesin inhibitors

Publications (1)

Publication Number Publication Date
PL1753723T3 true PL1753723T3 (pl) 2009-01-30

Family

ID=34970815

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05752901T PL1753723T3 (pl) 2004-05-21 2005-05-19 Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych

Country Status (19)

Country Link
US (2) US7452996B2 (pl)
EP (1) EP1753723B1 (pl)
JP (1) JP2008502721A (pl)
CN (1) CN1956960A (pl)
AT (1) ATE404536T1 (pl)
AU (1) AU2005245492A1 (pl)
BR (1) BRPI0511433A (pl)
CA (1) CA2564215A1 (pl)
DE (1) DE602005008953D1 (pl)
DK (1) DK1753723T3 (pl)
ES (1) ES2311992T3 (pl)
HR (1) HRP20080493T3 (pl)
MX (1) MXPA06011958A (pl)
PL (1) PL1753723T3 (pl)
PT (1) PT1753723E (pl)
RS (1) RS50670B (pl)
RU (1) RU2385867C2 (pl)
SI (1) SI1753723T1 (pl)
WO (1) WO2005113507A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1753723T3 (da) * 2004-05-21 2008-10-20 Novartis Vaccines & Diagnostic Substituerede quinolinderivater som mitotiske kinesininhibitorer
AU2005273705B8 (en) 2004-08-18 2010-01-28 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007056681A2 (en) * 2005-11-04 2007-05-18 Smithkline Beecham Corporation Methods for administering hypoglycemic agents
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
GEP20125389B (en) * 2006-11-13 2012-01-25 Novartis Ag Substituted pyrazole and triazole compounds as ksp inhibitors
US7820646B2 (en) * 2007-01-05 2010-10-26 Novartis Vaccines And Diagnostics, Inc. Cyclized derivatives as Eg-5 inhibitors
FR2940289B1 (fr) * 2008-12-23 2014-09-12 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas
EP2558452A2 (en) * 2010-04-15 2013-02-20 Novartis AG Oxazole and thiazole compounds as ksp inhibitors
JP2013523867A (ja) * 2010-04-15 2013-06-17 ノバルティス アーゲー Ｋｓｐ阻害剤としてのトリアゾール化合物
ES2841809T3 (es) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
US9458161B1 (en) 2011-11-03 2016-10-04 Vanderblit University TSPO ligands for cancer imaging and treatment
BR112015003192A2 (pt) * 2012-08-13 2017-08-08 Array Biopharma Inc arry-520 para uso no tratamento de câncer em um paciente com baixa aag
SI3524595T1 (sl) 2014-08-28 2022-10-28 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistosti in postopek njegove proizvodnje
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
BR112018002239A2 (pt) * 2015-08-19 2018-09-18 Eisai R&D Management Co., Ltd. agente terapêutico para câncer do trato biliar
KR102587702B1 (ko) 2015-08-20 2023-10-12 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
MX2019013014A (es) 2017-05-16 2020-08-06 Eisai R&D Man Co Ltd Tratamiento de carcinoma hepatocelular.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172087B1 (en) * 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
WO2000059887A1 (en) 1999-04-02 2000-10-12 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2001030768A1 (en) 1999-10-27 2001-05-03 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
KR20030060904A (ko) 2000-10-06 2003-07-16 뉴로젠 코포레이션 Ｃｒｆ 수용체 조절자로서 벤즈이미다졸 및 인돌 유도체
BR0116096A (pt) 2000-12-11 2005-10-18 Tularik Inc Composto, composição farmacêutica, e, métodos para tratar uma condição ou doença inflamatória ou imune em um paciente, para tratar uma condição ou doença mediada por cxcr3 em um paciente, e para a modulação da função de cxcr3 em uma célula
WO2002057244A1 (en) 2001-01-19 2002-07-25 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
WO2002056880A1 (en) 2001-01-19 2002-07-25 Cytokinetics, Inc. Triphenylmethane kinesin inhibitors
EP1444209A4 (en) 2001-11-07 2005-02-16 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN
US6753428B2 (en) 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
EP1481077B1 (en) 2001-12-06 2009-11-04 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1463733B1 (en) 2001-12-06 2007-09-05 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2467726A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
DE60232994D1 (de) 2001-12-06 2009-08-27 Merck & Co Inc Inhibitoren von mitotischem kinesin
EP1551812B1 (en) 2001-12-06 2009-03-04 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2472470A1 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
AU2003213092A1 (en) 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
EP1492487B1 (en) 2002-03-08 2009-11-11 Merck & Co., Inc. Mitotic kinesin inhibitors
DE60333094D1 (de) 2002-04-17 2010-08-05 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
CN100491358C (zh) 2002-05-09 2009-05-27 赛特凯恩蒂克公司 嘧啶酮类化合物、组合物及方法
JP2005530785A (ja) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
CA2483627A1 (en) 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003103575A2 (en) 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
EP1515949B1 (en) 2002-06-14 2007-03-14 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1515724B1 (en) 2002-06-14 2009-10-21 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1556357A4 (en) 2002-06-14 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003247891A1 (en) 2002-07-08 2004-01-23 Merck & Co., Inc. Mitotic kinesin binding site
US6949538B2 (en) 2002-07-17 2005-09-27 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004009036A2 (en) 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
EP1539180A4 (en) 2002-08-21 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
DK1753723T3 (da) * 2004-05-21 2008-10-20 Novartis Vaccines & Diagnostic Substituerede quinolinderivater som mitotiske kinesininhibitorer

Also Published As

Publication number Publication date
US20050261337A1 (en) 2005-11-24
DE602005008953D1 (de) 2008-09-25
BRPI0511433A (pt) 2007-12-11
US7452996B2 (en) 2008-11-18
ES2311992T3 (es) 2009-02-16
RU2006145336A (ru) 2008-06-27
PT1753723E (pt) 2008-11-19
RU2385867C2 (ru) 2010-04-10
DK1753723T3 (da) 2008-10-20
AU2005245492A1 (en) 2005-12-01
MXPA06011958A (es) 2006-12-15
JP2008502721A (ja) 2008-01-31
RS50670B (sr) 2010-06-30
EP1753723A1 (en) 2007-02-21
EP1753723B1 (en) 2008-08-13
WO2005113507A1 (en) 2005-12-01
ATE404536T1 (de) 2008-08-15
HRP20080493T3 (hr) 2009-02-28
SI1753723T1 (sl) 2009-04-30
CN1956960A (zh) 2007-05-02
US20090028858A1 (en) 2009-01-29
CA2564215A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
PT1753723E (pt) Derivados de quinolina substituída como inibidores de quinesina mitótica
TW200612958A (en) Substituted imidazole derivatives
MX2007004699A (es) Derivados de indol y bencimidazol.
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
MX2009007260A (es) Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
TW200801000A (en) Spiroindolinone derivatives
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
WO2011058474A8 (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
MX2012009186A (es) Pirrolidina-2-carboxamidas sustituidas.
TW200728307A (en) Novel spirochromanone derivatives
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
IL198979A (en) Enzyme inhibitors diacylglycerol o-acetyltransferase type 1
TW200833675A (en) Nicotinamide derivatives
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
MX2012003982A (es) Pirrolidinas n-substituidas.
IL193620A0 (en) Spiroindolinone derivatives
TN2009000049A1 (en) A pyrrolopyrazin as syk-kinase inhibitor
UA97256C2 (ru) Замещенные пиразолы и триазолы как ингибиторы кбв (кинезин-белок веретена)
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
WO2007017728A3 (en) Novel heterocyclic compounds
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MY156955A (en) Antifungal agents